Omada Health, Inc.
For the period ended Sep 30, 2025. Filed Nov 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 7, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
Item 1. Financial Statements (unaudited)
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except per-share data, unaudited)
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $198,627 | $76,392 |
| Accounts receivable, net (1) | 41,446 | 23,417 |
| Inventory | 3,148 | 3,296 |
| Deferred commissions, current | 3,228 | 3,017 |
| Prepaid expenses and other current assets | 8,449 | 6,937 |
| Total current assets | 254,898 | 113,059 |
| Property and equipment, net | 7,537 | 5,625 |
| Operating lease right-of-use asset | - | 447 |
| Deferred commissions, non-current | 8,742 | 9,214 |
| Intangible assets, net | 2,853 | 4,263 |
| Goodwill | 13,240 | 13,240 |
| Other assets | 199 | 5,044 |
| Total assets | $287,469 | $150,892 |
| Liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) | ||
| Current liabilities | ||
| Accounts payable | $5,344 | $4,168 |
| Accrued expenses and other current liabilities (2) | 37,622 | 29,840 |
| Operating lease liability, current | - | 415 |
| Deferred revenue (3) | 27,157 | 19,530 |
| Total current liabilities | 70,123 | 53,953 |
| Long term debt | - | 29,771 |
| Warrant liabilities, non-current | - | 2,252 |
| Other liabilities, non-current | - | 285 |
| Total liabilities | 70,123 | 86,261 |
| Commitments and contingencies (Note 6) | ||
| Redeemable convertible preferred stock, $0.001 par value per share; no shares and 120,689 shares authorized as of September 30, 2025 and December 31, 2024, respectively; no shares and 118,219 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively, net of issuance costs | - | 449,034 |
| Stockholders’ equity (deficit) | ||
| Common stock, $0.001 par value per share; 750,000 and 181,500 shares authorized as of September 30, 2025 and December 31, 2024, respectively; 57,887 and 8,157 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 58 | 8 |
| Additional paid-in capital | 679,191 | 59,555 |
| Accumulated deficit | (461,903) | (443,966) |
| Total stockholders’ equity (deficit) | 217,346 | (384,403) |
| Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) | $287,469 | $150,892 |
(1)Includes amounts from a related party of $29.3 million and $13.2 million as of September 30, 2025 and December 31, 2024, respectively.
(2)Includes amounts from a related party of $5.2 million and $2.2 million as of September 30, 2025 and December 31, 2024, respectively.
(3)Includes amounts from a related party of $20.3 million and $13.2 million as of September 30, 2025 and December 31, 2024, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.